RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2013

Marketwired

WESTBOROUGH, MA--(Marketwired - Aug 14, 2013) -   RXi Pharmaceuticals Corporation (OTCQX: RXIID), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today reported its financial results for quarter ended June 30, 2013, and provided a business update.

"The first half of 2013 has been a good one for RXi Pharmaceuticals, with steady progress -- in line with our planning and budget -- for our research and development activities," commented Dr. Geert Cauwenbergh, President and CEO of the Company. He added that, "Not only has the successful outcome of our first two Phase 1 studies provided us with the confirmation for safety and tolerance of RXI-109 in volunteers; they have also provided us with the pharmacological confirmation that RXI-109 acts in line with its expected mechanism of action. These two positive outcomes allow us to embark on Phase 2 clinical studies with an increased level of confidence."

Second Quarter 2013 and Recent Company Highlights

  • Announcement of positive results in first double blind study in healthy volunteers in RXI-109: In June 2012, we initiated our first clinical trial of RXI-109, known as Study 1201. Study 1201 enrolled fifteen subjects where each received an injection of RXI-109 in two separate areas on the abdomen and placebo injections in two other areas of the abdomen. In June 2013, we announced that Study 1201 did not cause significant side effects or toxicities and showed that RXI-109 significantly reduced the expression of CTGF protein in the wound area in a dose dependent manner 84 days after a single dose, suggesting a potent and long lasting effect on this key biomarker for abnormal scarring.

  • Commenced trading on the OTCQX marketplace: The OTCQX marketplace is reserved for high-quality U.S. companies that meet financial standards, undergo management reviews and provide timely news and disclosure to investors. On July 19, 2013, the Company's common stock was listed to the OTCQX from the OTCBB and began trading on the same day.

  • Announcement of positive data in second Phase 1 multi-dose study in healthy volunteers in RXI-109: In December 2012, we initiated a second Phase 1 clinical trial of RXI-109, known as Study 1202. Study 1202 enrolled nine subjects, during which subjects received intradermal injections of RXI-109 in four separate areas of the abdomen and placebo injections in four other areas of the abdomen, all of which were administered on multiple occasions over multiple weeks. In July 2013, we announced that multiple injections of RXI-109 were well tolerated with minimal and mild side effects. The treatment of RXI-109 in this study resulted in dose dependent silencing of CTGF mRNA in the treated areas 3 days after the last dose.

  • Announcement of application for listing on The NASDAQ Capital Market: On July 22, 2013, the Company announced that it had filed an application for approval to move the listing of its common stock to The NASDAQ Capital Market. The Company expects the application process to take approximately 6-8 weeks.

  • Completion of a 1-for-30 reverse stock split: On July 22, 2013, the Company announced a 1-for-30 reverse stock split of the Company's issued and outstanding shares of common stock. The reverse split was effective as of July 23, 2013 and began trading on a post-split basis at the open of the OTCQX on July 24, 2013.

Selected Financial Highlights

Cash and Cash Equivalents

At June 30, 2013, RXi had cash, cash equivalents, and short term investments of approximately $17.6 million, compared with $5.1 million at December 31, 2012.

Net Loss and Net Loss Applicable to Common Stockholders

The net loss for the three months ended June 30, 2013 was $2.0 million, including $0.4 million in non-cash share-based compensation expense, compared with a net loss of $7.6 million, including $0.2 million in non-cash share-based compensation expense, for the three months ended June 30, 2012. The decrease in the net loss of $5.6 million was primarily attributable to a one-time charge in the quarter ended June 30, 2012 of $6.2 million related to the fair value of common shares issued in exchange for the use of patent and technology rights.

The net loss for the six months ended June 30, 2013 was $16.4 million, including $1.1 million in non-cash share-based compensation expense, compared with a net loss of $9.5 million, including $0.4 million in non-cash share-based compensation expense, for the six months ended June 30, 2012. The increase in net loss of $6.9 million was primarily attributable to an increase of $6.1 million in expense related to the fair value of common shares issued in exchange for patent and technology rights and an increase of $0.7 million in non-cash share based compensation expense.

Net loss applicable to common stockholders for the three months ended June 30, 2013 was $4.4 million compared with a net loss applicable to common stockholders of $18.2 million for the comparable period in 2012. The decrease in net loss applicable to common stockholders of $13.8 million was primarily attributable to the aforementioned decrease in the net loss as compared to prior year and a one-time charge of $9.5 million during this period in the prior year related to the beneficial conversion feature of the Series A Preferred Stock issued.

Net loss applicable to common stockholders for the six months ended June 30, 2013 was $22.3 million compared with a net loss applicable to common stockholders of $20.1 million for the comparable period in 2012. The increase in net loss applicable to common stockholders of $2.2 million was primarily attributable to the aforementioned increase in net loss as compared to prior year and an increase of $4.8 million related to the fair value of dividends paid on the Series A convertible preferred stock offset by a decrease of $9.5 million related to the beneficial conversion feature of the Series A convertible preferred stock recorded in the second quarter of 2012.

Revenues

Total revenues for the three months ended June 30, 2013 was $0.2 million as compared with no revenue for the comparable period in 2012. The increase in total revenues for the three months ended June 30, 2013 was due to the recognition of work completed on the Company's government grants during the period.

Total revenues for the six months ended June 30, 2012 was $0.3 million as compared with no revenue for the comparable period in 2012. The increase in total revenues for the six months ended June 30, 2013 was due to the recognition of work completed on the Company's government grants during the period.

Research and Development Expenses

Research and development expenses for the three months ended June 30, 2013 were $1.2 million, compared with $6.9 million for the three months ended June 30, 2012. The decrease of $5.7 million is largely due to the one-time charge of $6.2 million, during the second quarter of 2012, related to the fair value of common shares issued in exchange for the use of patent and technology rights offset by an increase of $0.4 million in research and development expense due to clinical trial expenses for the Company's two Phase 1 clinical trials.

Research and development expenses for the six months ended June 30, 2013 were $15.0 million, compared with $8.1 million for the six months ended June 30, 2013. The increase of $6.9 million was primarily due to increases of $6.1 in expense related to the fair value of common shares issued in exchange for patent and technology rights, $0.5 million in research and development expense related to the Company's two Phase 1 clinical trials and $0.4 in employee stock-based compensation expense.

General and Administrative Expenses

General and administrative expenses for the three months ended June 30, 2013 were $1.0 million, compared with $0.7 million for the three months ended June 30, 2012. The increase in general and administrative expenses of $0.3 million was primarily related to an increase of $0.2 million in employee stock-based compensation expense.

General and administrative expenses for the six months ended June 30, 2013 were $1.7 million, compared with $1.5 million for the six months ended June 30, 2012. The increase in general and administrative expenses of $0.2 million was primarily related to an increase of $0.4 million in employee stock-based compensation expense offset by a decrease of $0.2 million in general and administrative expense related to lower personnel and board fees and expenses.

Series A Preferred Stock and Dividends

Accretion of Series A convertible preferred stock and dividends was $2.4 million for the three months ended June 30, 2013, compared with $10.6 million accretion of Series A convertible preferred stock and dividends for the comparable period in 2012. The decrease of $8.2 million is primarily due to the one-time charge of $9.5 million related to the beneficial conversion feature of the Series A convertible preferred stock recorded in the second quarter of 2012, offset by an increase of $1.3 million in the fair value of dividends paid on the Series A convertible preferred stock as compared with the same period in the prior year.

Accretion of Series A convertible preferred stock and dividends was $5.9 million for the six months ended June 30, 2013, compared with $10.6 million accretion of Series A convertible preferred stock and dividends for the comparable period in 2012. The decrease of $4.7 million is primarily due to the one-time charge of $9.5 million related to the beneficial conversion feature of the Series A convertible preferred stock recorded in the second quarter of 2012, offset by an increase of $4.8 million related to the fair value of dividends paid on the Series A convertible preferred stock as compared with the same period in the prior year.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTCQX: RXIID) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI-109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered human clinical trials in June 2012. For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "intend," "believe," "expect," "may," "should," "designed to," "will" and similar references. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109 and our other product candidates; the timing and future success of our clinical trials with RXI-109; our expectation that we will enter into a Phase 2 clinical trial for RXI-109; our ability to implement cost-saving measures; and statements about future expectations, including future expectations regarding our NASDAQ listing. Forward-looking statements are neither historical facts nor assurances of future performance. Instead they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others: the risk that our clinical trial with RXI-109 may not be successful in evaluating the safety and tolerability of RXI-109 or providing preliminary evidence of surgical scar reduction; the successful and timely completion of clinical studies; uncertainties regarding the regulatory process; the availability of funds and resources to pursue our research and development projects, including our clinical trials with RXI-109; general economic conditions; risks that NASDAQ may determine that we do not meet their initial listing criteria, that if the listing is approved it will not have the intended effects of improving access to certain investors, financing flexibility and liquidity; and those identified under "Risk Factors" in the Company's most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q and in other filings the Company periodically makes with the SEC. The Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.

   
RXi PHARMACEUTICALS CORPORATION (REGISTRANT)  
(A Development Stage Company)  
CONDENSED STATEMENTS OF OPERATIONS  
(Amounts in thousands, except share and per share data)  
(Unaudited)  
   
    For the Three     For the Three     For the Six     For the Six  
Months Ended     Months Ended     Months Ended     Months Ended  
June 30, 2013     June 30, 2012     June 30, 2013     June 30, 2012  
                                 
  Total revenues   $ 225     $ --       278     $ --  
                                   
  Research and development expense     1,213       6,947       14,985       8,100  
  General and administrative expense     977       716       1,652       1,468  
  Operating loss     (1,965 )     (7,663 )     (16,359 )     (9,568 )
  Interest income (expense)     4       (6 )     4       (27 )
  Other income, net     --       70       (3 )     71  
  Net loss     (1,961 )     (7,599 )     (16,358 )     (9,524 )
  Accretion of Series A convertible preferred stock and dividends     (2,399 )     (10,620 )     (5,946 )     (10,620 )
  Net loss applicable to common stockholders   $ (4,360 )   $ (18,219 )   $ (22,304 )   $ (20,144 )
Net loss per common share applicable to common stockholders:                                
  Basic and diluted loss per share   $ (0.39 )   $ (4.13 )   $ (2.52 )   $ (5.20 )
  Weighted average common shares outstanding:                                
  Basic and diluted     11,168,144       4,406,780       8,845,026       3,877,387  
                                 
   
RXi PHARMACEUTICALS CORPORATION (REGISTRANT)  
(A Development Stage Company)  
CONDENSED BALANCE SHEETS  
(Unaudited)  
   
    June 30,   December 31,  
2013   2012  
ASSETS              
Current assets:              
Cash and cash equivalents   $ 8,587   $ 5,127  
Restricted cash     53     53  
Short term investments     9,000     --  
Prepaid expenses and other current assets     209     212  
Total current assets     17,849     5,392  
Equipment and furnishings, net     147     198  
Other assets     --     2  
               
Total assets   $ 17,996   $ 5,592  
               
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)              
Current liabilities:              
Accounts payable   $ 358   $ 416  
Accrued expenses and other current liabilities     913     767  
Deferred revenue     239     491  
Current maturities of capital lease obligations     --     5  
Total current liabilities     1,510     1,679  
Deferred revenue, net of current portion     --     27  
Total liabilities     1,510     1,706  
Total convertible preferred stock     9,771     9,726  
Total stockholders' equity (deficit)     6,715     (5,840 )
Total liabilities, convertible preferred stock and stockholders' equity (deficit)   $ 17,996   $ 5,592  
               
Contact:
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com

Rates

View Comments (0)

Recommended for You

  • Tycoon buys 30 Rolls-Royces for Macau hotel

    A Hong Kong tycoon has placed the biggest ever order for Rolls-Royce cars, agreeing to buy 30 Phantoms to chauffeur guests at a luxury resort he's building in the global gambling capital of Macau. Stephen Hung's $20 million purchase surpasses the 14 Phantoms bought by Hong Kong's Peninsula Hotel in…

    Associated Press
  • A Lot's Changed Since You Graduated High School

    Including the cost of college tuition. Start saving for a child's education today with the MEFA® U.Fund College Investing Plan.

    AdChoicesFidelity InvestmentsSponsored
  • Tycoon's arrest sends shock wave through Russia

    Tycoon's arrest sends shock wave through Russia MOSCOW (AP) — The arrest of a Russian telecoms and oil tycoon has sent shock waves through the country's business community, with some fearing a return to the dark days of a decade ago, when the Kremlin asserted its power by imprisoning the country's…

    Associated Press
  • Before You Buy Alibaba, Check Out 4 Top China Stocks

    Before You Buy Alibaba, Check Out 4 Top China Stocks While investors gear up for Alibaba Group 's (BABA) hotly anticipated initial public offering, don't forget about other Chinese stocks that are worth keeping an eye on. Today's Young Guns Screen of

    Investor's Business Daily
  • Play

    Citi, Bank of America Offer Discounted Mortgages

    Citigroup and Bank of America will offer mortgages at discounted interest rates to help borrowers with low incomes or subprime credit. AnnaMaria Andriotis joins MoneyBeat. Photo: Getty.

    WSJ Live
  • Costco Stores in Canada to Stop Taking American Express

    “The credit card relationship between American Express and Costco Wholesale Canada will not be renewed when it expires” on Dec. 31, the company said today in an e-mail to Canadian customers. The message was attributed to Lorelle Gilpin, vice president of marketing and membership for Costco…

    Bloomberg
  • As Fed takes baby steps, Cramer's trick for profit

    In turn, Cramer says making money in the market, involves looking at the environment through the lens of the Fed. "The trick is to remember that they speak for the common person," Cramer said. "The Fed wants the common person to make money." With that backdrop always in mind, Cramer says it becomes…

    CNBC
  • "The Retiree Next Door": How successful retirees stretch their savings

    "The Retiree Next Door": How successful retirees stretch their savingsBy the time she hit her late 40s, Toni Eugenia wasn’t sure she would ever be able to retire. Eugenia, 56, a pharmacy technician who lived in Houston, was nearly $200,000 in debt and

    Yahoo Finance
  • Enjoy this refreshing Triple Play offer!

    Get FIOS TV Mundo starting at $79.99/mo. w/ no annual contract + 2-yr. price guarantee. Or sign for 2 yrs. & get a $300 prepaid Visa. Click here.

    AdChoicesVerizon FiOS ®Sponsored
  • CNBC Anchor Calls Out Fed-Hater Bill Fleckenstein In Startling Shouting Match

    CNBC Bill Fleckenstein of Fleckenstein Capital appeared on CNBC's Futures Now program on Tuesday. Futures Now host Jackie DeAngelis came out swinging, asking Fleckenstein right at the top if he was willing to admit that he had misunderstood monetary policy. Sounding taken aback, Fleckenstein…

    Business Insider
  • Beanie Babies creator's sentence debated in court

    Beanie Babies creator's sentence debated in court CHICAGO (AP) — Federal prosecutors seeking to put the billionaire creator of Beanie Babies in prison for hiding millions in Swiss bank accounts told appellate court judges Wednesday that the toymaker's sentence of probation threatens to erode the…

    Associated Press
  • Apple to unveil new iPads, operating system on Oct. 21 : report

    The company plans to unveil the sixth generation of its iPad and the third edition of the iPad mini, as well as its operating system OS X Yosemite, which has undergone a complete visual overhaul, the Internet news website said. Trudy Muller, a spokeswoman for Apple, declined to comment. The iPad is…

    Reuters
  • Gilead Stock Is Falling On These Drug Setbacks

    Gilead Stock Is Falling On These Drug Setbacks Gilead Sciences (GILD) shares are backsliding Wednesday on news that the patient drop-out rate for hepatitis C drug Sovaldi is quadruple that of clinical trials. In addition, the biotech's Phase 2 study results

    Investor's Business Daily
  • Margaritaville casino owners seek bankruptcy

    The owner of Biloxi's Margaritaville casino has filed for Chapter 11 bankruptcy protection Tuesday, only hours before a hearing where the landlord aimed to seize the property. The filing by MVB Holding LLC in U.S. Don Dornan, a lawyer for landlord Clay Point LLC, said the company had planned to ask…

    Associated Press
  • Embraer to sell 50 E-175 jets to Republic in $2.1 billion deal

    Brazil's Embraer SA, the world's third largest commercial planemaker, said on Wednesday it booked a firm order from U.S. The deal, which will be included in Embraer's order book for the third quarter, is valued at $2.1 billion, the planemaker said in a securities filing. The planes will be operated…

    Reuters
  • Chase Credit Cards

    Choose from cards with travel rewards, cash back, low interest, and more. Learn More.

    AdChoicesCreditcards.chase.comSponsored
  • Play

    What the Fed Meeting Means for Bonds

    Janet Yellen & Co. are expected to hint at their timetable for raising interest rates. Here's how investors should prepare ahead of the meeting.

    WSJ Live
  • Here's What Mark Cuban Wishes He Knew About Money In His 20s

    Cuban is the owner of the Dallas Mavericks basketball team. Billionaire investor and entrepreneur Mark Cuban is generous with his advice. When we asked him what he wishes he'd known about money in his 20s, he said:

    Business Insider
  • SHOE COMPANY: Our CEO Just Disappeared And Most Of The Money Is Gone

    "and like that: he's gone." This is an actual headline from a company press release: "CEO and COO disappeared, most of the company's cash missing." (Via FastFT) In a statement, German-based shoe company Ultrasonic said its CFO,  Chi Kwong Clifford Chan, has been unable to reach the company's CEO,…

    Business Insider
  • Billionaire Investor Says Chinese People Work Harder And Western Companies Could Face Deep Trouble After Alibaba IPO

    Michael Moritz, the chairman of VC firm Sequoia Capital, is a huge fan of Chinese internet companies and reiterated his enthusiasm for the Chinese market in an interview with The Wall Street Journal Wednesday. The billionaire investor described the Alibaba IPO as a “major landmark event” that is as…

    Business Insider
  • Top Analyst Upgrades and Downgrades: AEP, BHP, GE, Incyte, 3M, Tyco, Under Armour and More

    Top Analyst Upgrades and Downgrades: AEP, BHP, GE, Incyte, 3M, Tyco, Under Armour and More Stocks were firm on Wednesday morning ahead of the FOMC meeting outcome. Tuesday’s rally may have sparked higher interest again, and investors are looking for bargains

    24/7 Wall St.
  • 10 rock-solid stocks for conservative investors

    10 rock-solid stocks for conservative investors Shares with low volatility can beat their indexes with less risk Bloomberg News/Landov U.S. Bancorp is the cheapest S&P 500 stock

    MarketWatch
  • 1 Tip To Lose Belly Fat

    It's Hollywood's Hottest Diet And Gets Rid Of Stubborn Fat Areas Like Nothing Else.

    AdChoicesagoodcooksSponsored
  • 6 Things Debt Collectors Wish You Knew

    The work debt collectors do is not popular, and has become increasingly derided by those who don’t like what we do or simply don’t know the facts about debt collection. Too often, debt collection is painted with a broad brush to create a portrait that isn’t accurate, and doesn’t properly educate…

    Credit.com